115 lines
39 KiB
Text
115 lines
39 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548409">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548409/?report=reader">
|
|
<meta name="ncbi_pagename" content="Candesartan - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Candesartan - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Canakinumab/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Cangrelor/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Candesartan">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2017/01/13">
|
|
<meta name="citation_pmid" content="31643728">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548409/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Candesartan">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2017/01/13">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548409/">
|
|
<meta name="description" content="Candesartan is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure. Candesartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.">
|
|
<meta name="og:title" content="Candesartan">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Candesartan is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure. Candesartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548409/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Candesartan/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548409/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CB4D57D7B490100000000012100FB.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548409/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Canakinumab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Candesartan</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Cangrelor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548409/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548409/&text=Candesartan"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548409/?report=classic">Switch to classic view</a><a href="/books/NBK548409/pdf/Bookshelf_NBK548409.pdf">PDF (92K)</a><a href="/books/NBK548409/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548409%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CB4D57D7B490100000000012100FB.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548409_"><span class="title" itemprop="name">Candesartan</span></h1><p class="fm-aai"><a href="#_NBK548409_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Candesartan.OVERVIEW"><h2 id="_Candesartan_OVERVIEW_">OVERVIEW</h2><div id="Candesartan.Introduction"><h3>Introduction</h3><p>Candesartan is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure. Candesartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.</p></div><div id="Candesartan.Background"><h3>Background</h3><p>Candesartan (kan" de sar' tan) is an angiotensin II receptor blocker (ARB) that is widely used alone or in combination with other agents as therapy of hypertension and heart failure. Candesartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II, accounting for its antihypertensive activity. Candesartan was approved for use in the United States in 1998 and is available in 4, 8, 16 and 32 mg tablets generically and under the trade name Atacand. Current indications include treatment of hypertension (usually in combination with other agents) and to prevent cardiovascular events and death in patients with chronic heart failure. The typical dose of candesartan in adults is 16 to 32 mg once daily, and it is used long term. Candesartan is also available in fixed combinations with hydrochlorothiazide (Atacand HCT and others). Side effects of candesartan are uncommon, but may include headache, dizziness, fatigue, cough, gastrointestinal upset and fetal toxicity. Many ARBs, but not specifically candesartan, have been linked to cases of a severe sprue-like enteropathy that presents with severe diarrhea and weight loss and villous flattening and atrophy on intestinal biopsy arising after months or years of ARB use. The enteropathy resembles celiac disease but does not repond to a gluten-free diet, but resolves promptly with stopping the angiotensin receptor blocker.</p></div><div id="Candesartan.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Candesartan has been associated with a low rate of serum aminotransferase elevations (<1%) that in controlled trials was no higher than with placebo therapy. These elevations were transient and rarely required dose modification. Rare instances of clinically apparent acute liver injury have been reported in association with candesartan therapy. The onset is usually within 1 to 8 weeks of starting therapy and the serum enzyme pattern can be either hepatocellular or cholestatic with an acute hepatitis- or cholestatic hepatitis-like clinical syndrome. In some instances, cholestasis can be prolonged and relapsing, but candesartan therapy has not been associated with vanishing bile duct syndrome or chronic liver injury. Immunoallergic manifestations (rash, fever, eosinophilia) are not common, nor is autoantibody formation.</p><p>Likelihood score: C (Probable cause of rare instances of clinically apparent liver injury).</p></div><div id="Candesartan.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the minor serum aminotransferase elevations and the acute liver injury associated with candesartan is not known, but resembles idiosyncratic liver injury due to a hypersensitivity reaction. Candesartan has minor liver metabolism through the cytochrome P450 system (CYP 2C9) and has minimal drug-drug interactions.</p></div><div id="Candesartan.Outcome_and_Management"><h3>Outcome and Management</h3><p>The instances of acute liver injury reported with candesartan use have been self limited and have not resulted in acute liver failure or chronic liver injury. While corticosteroids have been used in cases of severe cholestasis due to ARBs, their efficacy has not been shown and their use is best avoided. Patients with candesartan induced acute liver injury should probably avoid use of other ARBs, although cross sensitivity to liver injury among the members of this class of agents has not been shown.</p><p>References on the safety and potential hepatotoxicity of candesartan are given in the Overview section on the angiotensin II receptor antagonists.</p><p>Drug Class: <a href="/books/n/livertox/AntihypertensiveAgen/?report=reader">Antihypertensive Agents</a>, <a href="/books/n/livertox/ARBs/?report=reader">Angiotensin II Receptor Antagonists</a></p><p>Other Drugs in the Subclass, Angiotensin II Receptor Antagonists: <a href="/books/n/livertox/Azilsartan/?report=reader">Azilsartan</a>, <a href="/books/n/livertox/Eprosartan/?report=reader">Eprosartan</a>, <a href="/books/n/livertox/Irbesartan/?report=reader">Irbesartan</a>, <a href="/books/n/livertox/Losartan/?report=reader">Losartan</a>, <a href="/books/n/livertox/Olmesartan/?report=reader">Olmesartan</a>, <a href="/books/n/livertox/Telmisartan/?report=reader">Telmisartan</a>, <a href="/books/n/livertox/Valsartan/?report=reader">Valsartan</a></p></div></div><div id="Candesartan.CASE_REPORT"><h2 id="_Candesartan_CASE_REPORT_">CASE REPORT</h2><div id="Candesartan.Case_1._Severe_hepatitis_att"><h3>Case 1. Severe hepatitis attributed to candesartan.</h3><p>[Modified from: Basile G, Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V. Candesartan cilexetil-induced severe hepatotoxicity. J Clin Gastroenterol 2003; 36: 273-5. <a href="https://www.ncbi.nlm.nih.gov/pubmed/12590242" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed Citation</a>]</p><p>A 61 year old woman with hypertension started therapy with candesartan cilexetil (16 mg daily) and developed fever, anorexia, nausea, abdominal pain and jaundice approximately 4 weeks later. She had no history of liver disease, alcohol abuse, risk factors for viral hepatitis or previous serious drug reactions. On examination, she had jaundice and low grade fever (37.8 oC). Laboratory tests showed marked elevations in serum bilirubin (27.2 mg/dL) and serum aminotransferase levels (ALT 918 U/L, AST 1367 U/L) with minimal increase in alkaline phosphatase (142 U/L), LDH (700 U/L: normal <460 U/L) and GGT (49 U/L) (Table). The prothrombin index was reduced at 52% (normal 70% to 120%). Tests for hepatitis A, B and C were negative and antinuclear antibody titers were minimally increased (1:40). Ultrasound and CT of the abdomen showed mild hepatomegaly and minimal ascites without evidence of biliary obstruction. A liver biopsy showed acute hepatocellular necrosis and inflammation but also cholestasis, ductopenia and biliary epithelial injury. There was mild fibrosis. Because of rising levels of serum bilirubin (peak 46.8 mg/dL), she was treated with a seven week course of methylprednisolone (40 mg/day for 3 weeks, 20 mg/day for 2 weeks, and 8 mg/day for two weeks). There was a gradual improvement in the patient’s condition and she was discharged after 8 weeks in the hospital. One month later, all liver tests were repeated and were normal.</p><div id="Candesartan.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCandesartanT1"><a href="/books/NBK548409/table/Candesartan.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figCandesartanT1" rid-ob="figobCandesartanT1"><img class="small-thumb" src="/books/NBK548409/table/Candesartan.T1/?report=thumb" src-large="/books/NBK548409/table/Candesartan.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Candesartan.T1"><a href="/books/NBK548409/table/Candesartan.T1/?report=objectonly" target="object" rid-ob="figobCandesartanT1">Table</a></h4></div></div></div><div id="Candesartan.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCandesartanT2"><a href="/books/NBK548409/table/Candesartan.T2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figCandesartanT2" rid-ob="figobCandesartanT2"><img class="small-thumb" src="/books/NBK548409/table/Candesartan.T2/?report=thumb" src-large="/books/NBK548409/table/Candesartan.T2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Candesartan.T2"><a href="/books/NBK548409/table/Candesartan.T2/?report=objectonly" target="object" rid-ob="figobCandesartanT2">Table</a></h4></div></div></div><div id="Candesartan.Comment"><h4>Comment</h4><p>The patient developed an acute hepatitis-like clinical syndrome one month after starting candesartan for hypertension. No other cause of acute liver injury was identified, and a liver biopsy showed changes that were compatible with drug induced liver disease (mixed hepatocellular and biliary injury). Corticosteroids were given because of the severity of the injury and recovery, while delayed, was ultimately complete within 8 to 12 weeks of onset. Whether the corticosteroids prompted or sped recovery is uncertain, but importantly, the methylprednisone dose was quickly lowered and stopped. Clinically apparent acute liver injury from angiotensin receptor antagonists is exceedingly rare, but the timing of onset and recovery and liver biopsy findings in this case were convincing. In view of the severity of the injury and the availability of other medications to treat hypertension, rechallenge with candesartan is not warranted.</p></div></div></div><div id="Candesartan.PRODUCT_INFORMATION"><h2 id="_Candesartan_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Candesartan.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Candesartan – Atacand®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Angiotensin II Receptor Antagonists</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Candesartan" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Candesartan.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Candesartan_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCandesartanT3"><a href="/books/NBK548409/table/Candesartan.T3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figCandesartanT3" rid-ob="figobCandesartanT3"><img class="small-thumb" src="/books/NBK548409/table/Candesartan.T3/?report=thumb" src-large="/books/NBK548409/table/Candesartan.T3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Candesartan.T3"><a href="/books/NBK548409/table/Candesartan.T3/?report=objectonly" target="object" rid-ob="figobCandesartanT3">Table</a></h4></div></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548409_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 13, 2017</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Candesartan. [Updated 2017 Jan 13].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Canakinumab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Cangrelor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobCandesartanT1"><div id="Candesartan.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548409/table/Candesartan.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Candesartan.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Candesartan.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Candesartan (16 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Candesartan.T1_1_1_1_1" id="hd_b_Candesartan.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Candesartan.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=13)</td></tr><tr><th headers="hd_h_Candesartan.T1_1_1_1_1" id="hd_b_Candesartan.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Candesartan.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">4+ (jaundice, prothrombin time prolongation and ascites)</td></tr><tr><th headers="hd_h_Candesartan.T1_1_1_1_1" id="hd_b_Candesartan.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">Latency:</th><td headers="hd_b_Candesartan.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td></tr><tr><th headers="hd_h_Candesartan.T1_1_1_1_1" id="hd_b_Candesartan.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Candesartan.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">8-12 weeks</td></tr><tr><th headers="hd_h_Candesartan.T1_1_1_1_1" id="hd_b_Candesartan.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Candesartan.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobCandesartanT2"><div id="Candesartan.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548409/table/Candesartan.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Candesartan.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Weeks After Starting</th><th id="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Weeks After Stopping</th><th id="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">ALT (U/L)</th><th id="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Bilirubin (mg/dL)</th><th id="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">918</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">142</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">27.2</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">386</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">39.1</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Corticosteroids started</td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">260</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">405</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">46.8</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">144</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">97</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">26.2</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">47</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">176</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">3.8</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13</td><td headers="hd_h_Candesartan.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">8</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">20</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">93</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Corticosteroids stopped</td></tr><tr><td headers="hd_h_Candesartan.T2_1_1_1_1 hd_h_Candesartan.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Candesartan.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><58</b>
|
|
</td><td headers="hd_h_Candesartan.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><117</b>
|
|
</td><td headers="hd_h_Candesartan.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Candesartan.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="boxed-text" id="figobCandesartanBPI"><div id="Candesartan.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Candesartan – Atacand®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Angiotensin II Receptor Antagonists</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Candesartan" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></article><article data-type="table-wrap" id="figobCandesartanT3"><div id="Candesartan.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548409/table/Candesartan.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Candesartan.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Candesartan.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Candesartan.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Candesartan.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Candesartan.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Candesartan.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Candesartan</td><td headers="hd_h_Candesartan.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135023846" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">139481-59-7</a>
|
|
</td><td headers="hd_h_Candesartan.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C24-H20-N6-O3</td><td headers="hd_h_Candesartan.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548409/bin/Candesartan_Structure.jpg" alt="Chemical Structure for Candesartan" /></div>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|